![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MRPL2 |
Gene summary for MRPL2 |
![]() |
Gene information | Species | Human | Gene symbol | MRPL2 | Gene ID | 51069 |
Gene name | mitochondrial ribosomal protein L2 | |
Gene Alias | CGI-22 | |
Cytomap | 6p21.1 | |
Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | C9IY40 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51069 | MRPL2 | LZE2T | Human | Esophagus | ESCC | 1.12e-08 | 1.74e+00 | 0.082 |
51069 | MRPL2 | LZE4T | Human | Esophagus | ESCC | 4.52e-10 | 2.76e-01 | 0.0811 |
51069 | MRPL2 | LZE5T | Human | Esophagus | ESCC | 1.06e-06 | 2.84e-01 | 0.0514 |
51069 | MRPL2 | LZE7T | Human | Esophagus | ESCC | 2.98e-07 | 5.02e-01 | 0.0667 |
51069 | MRPL2 | LZE8T | Human | Esophagus | ESCC | 4.70e-09 | 1.96e-01 | 0.067 |
51069 | MRPL2 | LZE20T | Human | Esophagus | ESCC | 2.24e-10 | 3.33e-01 | 0.0662 |
51069 | MRPL2 | LZE22D1 | Human | Esophagus | HGIN | 1.11e-05 | 2.30e-01 | 0.0595 |
51069 | MRPL2 | LZE22T | Human | Esophagus | ESCC | 1.38e-02 | 3.35e-01 | 0.068 |
51069 | MRPL2 | LZE24T | Human | Esophagus | ESCC | 4.55e-24 | 6.44e-01 | 0.0596 |
51069 | MRPL2 | LZE6T | Human | Esophagus | ESCC | 4.86e-06 | 5.31e-01 | 0.0845 |
51069 | MRPL2 | P1T-E | Human | Esophagus | ESCC | 1.62e-15 | 6.83e-01 | 0.0875 |
51069 | MRPL2 | P2T-E | Human | Esophagus | ESCC | 2.03e-27 | 6.00e-01 | 0.1177 |
51069 | MRPL2 | P4T-E | Human | Esophagus | ESCC | 1.09e-33 | 9.99e-01 | 0.1323 |
51069 | MRPL2 | P5T-E | Human | Esophagus | ESCC | 3.64e-45 | 8.66e-01 | 0.1327 |
51069 | MRPL2 | P8T-E | Human | Esophagus | ESCC | 1.96e-26 | 5.31e-01 | 0.0889 |
51069 | MRPL2 | P9T-E | Human | Esophagus | ESCC | 2.08e-25 | 6.39e-01 | 0.1131 |
51069 | MRPL2 | P10T-E | Human | Esophagus | ESCC | 4.71e-25 | 4.09e-01 | 0.116 |
51069 | MRPL2 | P11T-E | Human | Esophagus | ESCC | 9.57e-17 | 6.77e-01 | 0.1426 |
51069 | MRPL2 | P12T-E | Human | Esophagus | ESCC | 2.26e-36 | 5.84e-01 | 0.1122 |
51069 | MRPL2 | P15T-E | Human | Esophagus | ESCC | 6.80e-24 | 5.47e-01 | 0.1149 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:014005311 | Prostate | Tumor | mitochondrial gene expression | 31/3246 | 108/18723 | 2.31e-03 | 1.30e-02 | 31 |
GO:002261329 | Skin | cSCC | ribonucleoprotein complex biogenesis | 302/4864 | 463/18723 | 5.13e-72 | 3.22e-68 | 302 |
GO:004225428 | Skin | cSCC | ribosome biogenesis | 206/4864 | 299/18723 | 3.33e-55 | 1.04e-51 | 206 |
GO:007182629 | Skin | cSCC | ribonucleoprotein complex subunit organization | 140/4864 | 227/18723 | 5.54e-30 | 3.16e-27 | 140 |
GO:002261829 | Skin | cSCC | ribonucleoprotein complex assembly | 136/4864 | 220/18723 | 2.60e-29 | 1.25e-26 | 136 |
GO:004227328 | Skin | cSCC | ribosomal large subunit biogenesis | 57/4864 | 72/18723 | 4.90e-21 | 8.53e-19 | 57 |
GO:004225529 | Skin | cSCC | ribosome assembly | 44/4864 | 61/18723 | 5.84e-14 | 3.81e-12 | 44 |
GO:00325436 | Skin | cSCC | mitochondrial translation | 47/4864 | 76/18723 | 4.70e-11 | 2.22e-09 | 47 |
GO:01400535 | Skin | cSCC | mitochondrial gene expression | 56/4864 | 108/18723 | 8.06e-09 | 2.56e-07 | 56 |
GO:000002728 | Skin | cSCC | ribosomal large subunit assembly | 19/4864 | 27/18723 | 1.72e-06 | 2.88e-05 | 19 |
GO:002261330 | Thyroid | HT | ribonucleoprotein complex biogenesis | 74/1272 | 463/18723 | 4.05e-12 | 8.05e-10 | 74 |
GO:002261830 | Thyroid | HT | ribonucleoprotein complex assembly | 43/1272 | 220/18723 | 2.57e-10 | 3.25e-08 | 43 |
GO:007182630 | Thyroid | HT | ribonucleoprotein complex subunit organization | 43/1272 | 227/18723 | 7.18e-10 | 8.12e-08 | 43 |
GO:004225530 | Thyroid | HT | ribosome assembly | 20/1272 | 61/18723 | 1.61e-09 | 1.72e-07 | 20 |
GO:004225429 | Thyroid | HT | ribosome biogenesis | 48/1272 | 299/18723 | 2.16e-08 | 1.70e-06 | 48 |
GO:004227329 | Thyroid | HT | ribosomal large subunit biogenesis | 19/1272 | 72/18723 | 2.08e-07 | 1.07e-05 | 19 |
GO:000002729 | Thyroid | HT | ribosomal large subunit assembly | 9/1272 | 27/18723 | 4.58e-05 | 9.27e-04 | 9 |
GO:0022613113 | Thyroid | PTC | ribonucleoprotein complex biogenesis | 292/5968 | 463/18723 | 3.24e-44 | 2.05e-40 | 292 |
GO:0042254113 | Thyroid | PTC | ribosome biogenesis | 202/5968 | 299/18723 | 3.47e-37 | 5.47e-34 | 202 |
GO:0071826113 | Thyroid | PTC | ribonucleoprotein complex subunit organization | 134/5968 | 227/18723 | 2.34e-17 | 2.24e-15 | 134 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301039 | Esophagus | HGIN | Ribosome | 108/1383 | 167/8465 | 1.44e-45 | 4.71e-43 | 3.74e-43 | 108 |
hsa03010115 | Esophagus | HGIN | Ribosome | 108/1383 | 167/8465 | 1.44e-45 | 4.71e-43 | 3.74e-43 | 108 |
hsa03010211 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
hsa03010310 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
hsa0301022 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
hsa0301032 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
hsa0301042 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
hsa0301052 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
hsa0301030 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
hsa03010114 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
hsa03010210 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
hsa0301038 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MRPL2 | SNV | Missense_Mutation | novel | c.452T>G | p.Ile151Ser | p.I151S | Q5T653 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MRPL2 | SNV | Missense_Mutation | c.724N>T | p.Ala242Ser | p.A242S | Q5T653 | protein_coding | deleterious(0.01) | possibly_damaging(0.797) | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
MRPL2 | SNV | Missense_Mutation | c.102N>A | p.Met34Ile | p.M34I | Q5T653 | protein_coding | tolerated_low_confidence(0.57) | benign(0) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
MRPL2 | SNV | Missense_Mutation | rs201420185 | c.835N>A | p.Gly279Arg | p.G279R | Q5T653 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
MRPL2 | SNV | Missense_Mutation | c.372G>C | p.Glu124Asp | p.E124D | Q5T653 | protein_coding | deleterious(0.04) | possibly_damaging(0.808) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
MRPL2 | deletion | Frame_Shift_Del | novel | c.126delN | p.Ser43LeufsTer3 | p.S43Lfs*3 | Q5T653 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
MRPL2 | SNV | Missense_Mutation | novel | c.405N>T | p.Arg135Ser | p.R135S | Q5T653 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A950-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
MRPL2 | SNV | Missense_Mutation | rs532734983 | c.512N>A | p.Arg171Gln | p.R171Q | Q5T653 | protein_coding | tolerated(0.06) | probably_damaging(0.998) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MRPL2 | SNV | Missense_Mutation | c.830N>A | p.Arg277His | p.R277H | Q5T653 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MRPL2 | SNV | Missense_Mutation | novel | c.187N>G | p.Phe63Val | p.F63V | Q5T653 | protein_coding | tolerated(0.55) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |